Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment
Summary
The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.
What changed
The USPTO issued patent grant US12600715B2 to Boehringer Ingelheim International GmbH, granting exclusive rights to methods of treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their salts. The patent covers multiple therapeutic indications including respiratory conditions, dermatological applications, pain management, and immunological disorders. The filing date was November 2, 2023, and the patent includes 20 claims.
For pharmaceutical companies and biotechnology firms developing treatments for systemic sclerosis or related fibrotic conditions, this patent establishes proprietary intellectual property that may restrict competitive entry using similar sGC activator compounds. Developers should conduct freedom-to-operate analyses before advancing similar therapeutic candidates through clinical development to assess potential infringement exposure.
What to do next
- Monitor for potential infringement by competing drug developers
- Consider patent enforcement actions if infringement is identified
- Review patent claims for freedom-to-operate assessments
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Soluble guanylate cyclate activators for treating systemic sclerosis
Grant US12600715B2 Kind: B2 Apr 14, 2026
Assignee
Boehringer Ingelheim International GmbH
Inventors
Mary Ruth Flack, Julia Kaufman, Indra Sethy-Coraci
Abstract
The present invention relates to methods for treating patients with systemic sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I),
or a pharmaceutically acceptable salt thereof, where R1-R7 and A are as defined herein.
CPC Classifications
C07D 405/14 A61P 11/00 A61P 17/00 A61P 17/02 A61P 29/00 A61P 37/00 A61K 31/553 A61K 31/4725
Filing Date
2023-11-02
Application No.
18386267
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.